• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Latest News about Eisai Co Ltd

Recent news which mentions Eisai Co Ltd

Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
January 15, 2025
Tags Health care industry Health & Science Companies
From CNBC.com News
Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction
October 30, 2024
Tags Biotech and Pharmaceuticals Breaking news Earnings
From CNBC.com News
5 things to know before the stock market opens Monday
September 09, 2024
Tags Tesla Inc General Motors Co Politics
From CNBC.com News
Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment
September 08, 2024
Tags Health & Science Companies Eisai Co Ltd
From CNBC.com News
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
July 30, 2024
Tags Biogen Inc US: News Pharmaceuticals
From CNBC.com News
Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
July 30, 2024
Tags Eisai Co Ltd Companies Health & Science
From CNBC.com News
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
July 26, 2024
Tags Biogen Inc US: News Pharmaceuticals
From CNBC.com News
Jim Cramer says Eli Lilly isn't a 'one trick pony' after FDA advisers endorse its Alzheimer's drug
June 11, 2024
Tags Investing stocks Eli Lilly and Co
From CNBC.com News
Biogen tops quarterly profit estimates as cost cuts take hold, Leqembi launch picks up
April 24, 2024
Tags Biogen Inc US: News Pharmaceuticals
From CNBC.com News
Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move
March 08, 2024
Tags Health & Science Eisai Co Ltd Companies
From CNBC.com News
Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start
February 20, 2024
Tags Science Healthy Returns Biotech and Pharmaceuticals
From CNBC.com News
Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
February 13, 2024
Tags Biotechnology Earnings Business
From CNBC.com News
Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments
January 31, 2024
Tags Biotech and Pharmaceuticals Social issues Business News
From CNBC.com News
Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma
December 20, 2023
Tags Amgen Inc Eisai Co Ltd Companies
From CNBC.com News
Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops
December 02, 2023
Tags Biotech and Pharmaceuticals Pfizer Inc Business News
From CNBC.com News
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study
October 25, 2023
Tags Health care industry Eisai Co Ltd Companies
From CNBC.com News
5 things to know before the stock market opens Tuesday
July 18, 2023
Tags Technology Business Business News
From CNBC.com News
Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year
July 17, 2023
Tags Breaking news Biotech and Pharmaceuticals Alzheimer's disease
From CNBC.com News
Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know
July 08, 2023
Tags U/S/ Economy Social issues Biotech and Pharmaceuticals
From CNBC.com News
Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024
July 07, 2023
Tags Pharmaceuticals US: News Biogen Inc
From CNBC.com News
Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more
July 07, 2023
Tags Biogen Inc Finance Levi Strauss & Co
From CNBC.com News
Japanese pharma Eisai slides 4% despite FDA approval for Alzheimer's drug
July 07, 2023
Tags Asia Markets Pharmaceuticals Eisai Co Ltd
From CNBC.com News
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage
July 06, 2023
Tags Social issues Biotech and Pharmaceuticals Breaking News: Business
From CNBC.com News
FDA advisors to weigh whether Alzheimer's drug Leqembi should receive full approval
June 09, 2023
Tags Breaking News: Business Science Business
From CNBC.com News
Bernie Sanders says price of Alzheimer's treatment is unconscionable, calls on HHS to take action
June 07, 2023
Tags Biogen Inc US: News Eisai Co Ltd
From CNBC.com News
Alzheimer's treatment Leqembi could cost Medicare up to $5 billion per year, study estimates
May 12, 2023
Tags Eli Lilly and Co US: News Biogen Inc
From CNBC.com News
Bipartisan attorneys general call on Medicare to cover Alzheimer's treatments
May 01, 2023
Tags Politics Policy Pandemics
From CNBC.com News
Alzheimer’s patients may wait years to get treated with new drugs, putting them at risk of more severe disease
April 30, 2023
Tags CVS Health Corp Biogen Inc Eli Lilly and Co
From CNBC.com News
Alzheimer's: Medicare will cover Leqembi for all patients if FDA approves drug, CMS chief says
April 26, 2023
Tags Business News Policy Pandemics
From CNBC.com News
Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
April 25, 2023
Tags US: News Biogen Inc Pharmaceuticals
From CNBC.com News
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap